Sling Therapeutics' $123M Raise Led Southeast Michigan VC in Q3

Sling Therapeutics Inc. raised $123 million in the third quarter, the largest venture capital deal in Southeast Michigan and the anchor of a biotech-led surge in regional funding.

The raise, first reported by Crain's Detroit Business on October 8, came as investors concentrated capital in a relatively small number of larger deals rather than spreading it across many smaller checks. The pattern defined the quarter for the region's startup ecosystem.

Ann Arbor startups drove the surge, according to Crain's reporter Anna Fifelski. The city, home to the University of Michigan's research infrastructure, produced the quarter's headline transactions — with life sciences companies taking the lead.

What does the $123 million deal signal?

The size of the Sling Therapeutics round stands out. A single $123 million commitment towers over the typical early-stage check written in Midwest markets, and it signals that institutional investors are willing to write growth-scale capital into Southeast Michigan biotech.

The concentration trend matters for founders. When investors cluster around fewer, bigger deals, startups outside the favored sectors and stages face a tighter funding environment even as headline regional totals rise.

Which companies shaped the quarter?

Biotech and life sciences tools companies dominated the deal flow. Among the region's active players is Akadeum Life Sciences, an Ann Arbor-area company whose technology uses microbubbles to process T-cells from an entire blood bag in under one hour — a capability aimed at cell therapy manufacturing.

The company's product image accompanied Crain's quarterly ranking of the region's biggest VC deals, underscoring how deeply the life sciences segment ran through Q3's transaction list.

Why Ann Arbor?

The Q3 data reinforces Ann Arbor's position as Southeast Michigan's venture capital hub. The city's startups claimed the top of the regional deal table, led by Sling Therapeutics' nine-figure round.

For the broader Detroit regional economy, the quarter adds venture-backed innovation to a story otherwise dominated this fall by bank consolidation — including Fifth Third's deal for Comerica, which reshaped the ranking of Michigan's largest banks, and Bank of Ann Arbor's $52 million acquisition of an Oakland County bank.

What comes next?

The concentration of capital in large biotech deals raises a clear question for Q4: whether Southeast Michigan can convert headline raises into a broader base of funded startups, or whether the region's venture totals will continue to hinge on a handful of Ann Arbor life sciences rounds.